HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PPI 2458

a methionine aminopeptidase-2 inhibitor with antirheumatic activity; structure in first source

Also Known As:

PPI-2458; PPI2458

Networked: 10 relevant articles (3 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Ethers: 242
  - Cyclic Ethers: 12
    - Epoxy Compounds: 689
      - PPI 2458: 10
Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Branched-Chain Amino Acids: 2289
    - Valine: 1999
      - PPI 2458: 10
  - Essential Amino Acids: 1152
    - Valine: 1999
      - PPI 2458: 10

Experts

1.	Labenski, Matthew T: 4 articles (04/2013 - 07/2004)
2.	Thompson, Charles D: 4 articles (04/2013 - 07/2004)
3.	Hannig, Gerhard: 4 articles (03/2007 - 07/2004)
4.	Westlin, William F: 4 articles (03/2007 - 07/2004)
5.	Bernier, Sylvie G: 3 articles (03/2007 - 07/2004)
6.	Karp, Russell M: 3 articles (03/2007 - 04/2006)
7.	Ashraf, Sadaf: 2 articles (09/2011 - 07/2010)
8.	Mapp, Paul I: 2 articles (09/2011 - 07/2010)
9.	Walsh, David A: 2 articles (09/2011 - 07/2010)
10.	Doyle, Beth: 2 articles (03/2007 - 07/2004)

Related Diseases

1.	Arthritis (Polyarthritis) 03/01/2007 - "In the rat PG-PS arthritis model, PPI-2458 afforded significant protection against established disease after therapeutic dosing. " 01/01/2007 - "Our study showed PPI-2458 was able to reduce clinical signs of arthritis in both acute and chronic CIA models. " 01/01/2008 - "The important role that MetAP-2 has in the pathophysiological disease processes of PG-PS arthritis provides a strong rationale for evaluating PPI-2458 as a disease modifying antirheumatic treatment for rheumatoid arthritis." 07/20/2004 - "We suggest that the mechanism of PPI-2458 action, highly selective and potent anti-proliferative activity on HFLS-RA and HUVEC in vitro, a significantly improved CNS toxicity profile, and marked attenuation of chronic disease in the rat peptidoglycan-polysaccharide arthritis model in vivo, positions this compound as a drug for the treatment of RA." 07/20/2004 - "In the rat model of peptidoglycan-polysaccharide-induced arthritis, PPI-2458 significantly attenuated paw swelling when therapeutically administered after the onset of chronic disease. "
2.	Rheumatoid Arthritis 07/20/2004 - "A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis." 01/01/2008 - "The important role that MetAP-2 has in the pathophysiological disease processes of PG-PS arthritis provides a strong rationale for evaluating PPI-2458 as a disease modifying antirheumatic treatment for rheumatoid arthritis." 01/01/2008 - "An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis."
3.	Seizures (Absence Seizure) 07/20/2004 - "The CNS toxicity profile of PPI-2458, determined by the incidence of seizures, is significantly improved over that of the parental compound TNP-470. "
4.	Osteitis 03/01/2007 - "This in vivo activity of PPI-2458 was linked to the inhibition of methionine aminopeptidase type 2. Histopathologic assessment of affected joints showed improvement in processes of inflammation, bone resorption, and cartilage erosion, associated with significant improvement in all clinical indices. "
5.	Chronic Disease (Chronic Diseases) 07/20/2004 - "We suggest that the mechanism of PPI-2458 action, highly selective and potent anti-proliferative activity on HFLS-RA and HUVEC in vitro, a significantly improved CNS toxicity profile, and marked attenuation of chronic disease in the rat peptidoglycan-polysaccharide arthritis model in vivo, positions this compound as a drug for the treatment of RA." 07/20/2004 - "In the rat model of peptidoglycan-polysaccharide-induced arthritis, PPI-2458 significantly attenuated paw swelling when therapeutically administered after the onset of chronic disease. "

Related Drugs and Biologics

1.	Methionine (L-Methionine)
2.	Aminopeptidases
3.	Polysaccharides (Glycans)
4.	Peptidoglycan (Murein)
5.	O-(Chloroacetylcarbamoyl)fumagillol (TNP 470)
6.	PPI 2458
7.	methionine aminopeptidase 2
8.	fumagillin
9.	Esters
10.	carbamic acid (ammonium carbamate)

Related Therapies and Procedures

1.	Molecular Targeted Therapy